Podcasts about IQVIA

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: FDA approves the first fast-acting biosimilar insulin in the US, Tandem issues warning, DOJ stands up for remote monitoring in schools, GLP1 use protects against dementia, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX We've got the first and only biosimilar FDA approved and moving to market. Kirsty – insulin aspart, which is a biosimilar to Novolog will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use. KIRSTY has been available in Europe and Canada since 2022. This same company makes Semglee, the first biosimilar for long acting? Sales of Insulin Aspart in the United States were approximately $1.9 billion in 2024, according to IQVIA. https://www.globenewswire.com/news-release/2025/07/15/3115973/0/en/Biocon-Biologics-Expands-Diabetes-Portfolio-with-FDA-Approval-of-Kirsty-the-First-and-Only-Interchangeable-Rapid-Acting-Insulin-Aspart-in-the-United-States.html XX Tandem Diabetes Care (Nasdaq:TNDM) has issued an urgent medical device correction for some t:slim X2 automated insulin pumps. In a July 22 notice, the San Diego-based company warned of pumps that may exhibit a higher rate of speaker failure. During normal use, the insulin pump software monitors current flowing through the speaker during use. Measurements that fall within a pre-determined range indicate a functioning speaker. Meanwhile, measurements falling outside the range indicate a speaker failure.   When the measurements land outside the expected range, the system declares a malfunction, referred to as “Malfunction 16.” If the pump declares this malfunction, insulin delivery will stop and the pump will no longer be operational. Malfunction 16 terminates communication between the pump and continuous glucose monitor (CGM), as well as the t:slim mobile app.   If not addressed, the issue can lead to hyperglycemia, which can result in hospitalization or medical intervention. The company reports 700 adverse events and 59 reported injuries to date, with no reports of death.   Tandem identified that certain speaker versions have a higher rate of Malfunction 16 events due to a wiring issue within the speaker. Users can continue using their pump but with added precautions because Malfunction 16 can occur at any time. They should use the t:slim mobile app with push notifications turned on so the app alerts them if the malfunction occurs, the company said.   Additionally, Tandem intends to release a software update aimed at enhancing the early detection of speaker failure. The update also introduces persistent vibration alarms to help reduce potential safety risk. Tandem plans to notify affected pump users when it makes the update available. https://www.drugdeliverybusiness.com/tandem-warns-insulin-pump-speaker-malfunction/ XX BIG WIN! The DOJ protects T1D rights again! The US Attorney's office for the Western District of Washington State reached a settlement with a public school district that once again confirms remotely monitoring students' CGMs is a reasonable accommodation that schools must provide to comply with the Americans with Disabilities Act. If its true for one state its true for all states under federal law! If your local schools still refuse to remotely monitor CGMs of their students, provide them with this letter to compel them to FOLLOWT1Ds and FOLLOW Federal Laws. If they still refuse contact us! https://followt1ds.org/ XX new study finds people taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin users. Past studies show that people who have type 2 diabetes — a chronic condition where the body does not use its insulin properly — are at a higher risk of developing dementia. The study found that when comparing the neuroprotective abilities of two diabetes medications — metformin and glucagon-like peptide-1 receptor agonists (GLP-1 agonists) — participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin.   https://www.medicalnewstoday.com/articles/glp-1s-may-offer-better-dementia-protection-than-metformin XX Front office changes coming to Dexcom.  CEO Kevin Sayer will step down  & give the reins to current Chief Operating Officer Jake Leach. Scheduled for January 1, 2026, Leach will also join Dexcom's board of directors where Sayer will remain  executive chairman. One of our frequent guests here.. Leach has worked at Dexcom for 21 years. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. https://www.medtechdive.com/news/dexcom-ceo-change-kevin-sayer-jake-leach/756382/ XX A major international study has revealed that many children and young adults in Sub-Saharan Africa who are diagnosed with type 1 diabetes (T1D) may actually have a different, non-immune-based form of the condition. Unlike the traditional autoimmune version of T1D, this form appears to develop without the immune system attacking the insulin-producing cells. This finding could significantly reshape how diabetes is diagnosed and treated across the region, potentially leading to more precise care and better health outcomes. The researchers found that many young people in Sub-Saharan Africa diagnosed with T1D often don't have the usual markers in their blood (called islet autoantibodies) typically seen in people with T1D in other parts of the world. Specifically, 65% of participants with T1D in this region did not have islet autoantibodies. When the researchers compared this data to studies in the U.S., they found a smaller but significant proportion (15%) of Black participants diagnosed with T1D had a similar form of diabetes found in Sub-Saharan Africa – characterized by negative autoantibodies and a low T1D genetic risk score.   However, white Americans with T1D showed the typical autoimmune pattern, even if they didn't have detectable autoantibodies, their genetics still pointed to autoimmune diabetes.   “The identification of this T1D diabetes subtype in Sub-Saharan African populations and among individuals of African ancestry in the U.S. suggests a potential ancestral or genetic link,” Dabelea notes. “These findings highlight the need to consider alternative etiologies in this group and a deeper understanding of the underlying mechanisms may provide important insights for future prevention and treatment strategies.”     https://scitechdaily.com/new-diabetes-subtype-discovered-in-africa-challenges-global-assumptions/   XX Formal recognition for the specialty of Diabetology.   Diabetology is the specialty focused on the full continuum of diabetes care — encompassing diagnosis, treatment, prevention, technology integration, education, and cardiometabolic management. While it intersects with endocrinology, primary care, and public health, diabetology is uniquely defined by its depth and focus on diabetes alone.       The American College of Diabetology (ACD) is the national professional organization representing clinicians who specialize in diabetes care. ACD advances clinical excellence and education to improve the lives of those affected by diabetes. https://www.businesswire.com/news/home/20250725766248/en/American-College-of-Diabetology-Announces-Formal-Taxonomy-Classification-for-Diabetology   XX Tidepool announces cloud-to-cloud integration with Abbott's FreeStyle Libre portfolio. From the release: This integration allows people living with diabetes using the FreeStyle Libre portfolio to connect their data to their Tidepool account seamlessly. For healthcare providers, this means more comprehensive insights and streamlined workflows, with FreeStyle Libre systems data flowing continuously into the Tidepool Data Platform. https://www.tidepool.org/blog/abbott-freestyle-libre-integration-launched XX Stelo dexom ai food XX With high drug prices remaining an ongoing concern for U.S. politicians, Roche is considering following in the footsteps of some of its peers with a direct-to-consumer (DTC) model to cut out the middlemen.     About 50% of the money spent on drugs in the U.S. healthcare system goes straight to PBMs instead of the companies that create the medicines, Roche CEO Thomas Schinecker called out in a press conference on Thursday.   Bringing the drugs directly to the consumer could be a solution to positively impact pricing for patients “without destroying innovation,” Schinecker added on a separate Thursday call with investors, noting that the company has discussed the matter with the U.S. government and its Department of Health and Human Services. The pricing talks come after President Donald Trump inked a “Most Favored Nation” executive order in May, aiming to tie U.S. drug prices to lower prices in other developed nations. The plan was quickly called out by industry voices such as the PhRMA trade group, which labeled it a “bad deal” for U.S. patients. https://www.fiercepharma.com/pharma/roche-weighing-direct-consumer-drug-sales-ease-us-drug-pricing-woes-cut-out-pbms-ceo-says XX SAB BIO secures substantial $175M financing to advance T1D therapy with impressive investor lineup and extended cash runway until 2028. Most critically, this financing fully funds the pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune Type 1 diabetes in newly diagnosed patients. By extending the cash runway into mid-2028, SAB has effectively eliminated near-term financing risk and provided clear visibility through this crucial clinical trial and potential commercialization preparation. Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners         https://www.stocktitan.net/news/SABS/sab-bio-announces-oversubscribed-175-million-private-fwsf2t91ek4z.html   XX In a landmark 14-year study, researchers have found that artificially sweetened drinks raise the risk of developing type 2 diabetes by more than a third, significantly higher than those loaded with sugar. It challenges the long-standing perception of diet drinks being a healthier alternative and suggests they may carry metabolic risks of their own. In the first longitudinal study of its kind, led by Monash University, researchers tracked 36,608 participants over an average period of 13.9 years to assess how both sugar-sweetened beverages (SSBs) and artificially sweetened beverages (ASBs) impacted health outcomes. The self-reported health data, from the Melbourne Collaborative Cohort Study, was drawn from participants aged 40 to 69 years at the time of recruitment.   What they found was that drinking just one can of artificially sweetened soda increased the risk of developing type 2 diabetes by 38%, compared to people who didn't consume these drinks at all. For those consuming the same amount of sugary drinks, the risk was 23% higher. This suggests there's more than obesity at play. The researchers believe this result is due to an independent metabolic effect, possibly gut microbiome disruption or a change in glucose metabolism.   While the study didn't identify which artificial sweeteners were at play,   Evidence suggests that artificial sweeteners can alter the composition and function of gut bacteria, leading to glucose intolerance – a precursor to type 2 diabetes. And that some sweeteners may trigger insulin release, desensitize metabolic responses over time, or confuse the body's glucose regulation system – even without actual sugar in the picture.   Another hypothesis is that regular exposure to the kind of intense sweetness that artificial products deliver may condition the body to anticipate sugar calories that never come, affecting appetite regulation, insulin sensitivity and broader metabolic pathways. However, the authors suggest that how sweeteners affect the gut microbiota and glucose regulation are the most likely drivers of increased diabetes risk.   https://newatlas.com/diet-nutrition/one-drink-diabetes-risk/ XX After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an affordability challenge to the state and Marylanders.   The state Prescription Drug Affordability Board approved two resolutions saying that prescription drugs Jardiance and Farxiga likely pose an “an affordability challenge for the state health care system” and the state should look for ways to bring down those costs.   Health care advocates call the long-awaited resolution an “important first step” in the process in bringing down prescription costs for those on the state's health plan.       That milestone has been years in the making. Created in 2019 by the General Assembly, the Prescription Drug Affordability Board was slow to launch due in part to a veto from former Gov. Larry Hogan (R) amid pandemic-induced economic uncertainty in 2020 that delayed the board's formation. The board also cited out-of-pocket costs for consumers and state and local spending on those drugs as indicators that there may be an affordability challenge.   The board will now look at options to address the potential affordability challenge, which could include setting an upper payment limit on those drugs. But it's not clear when the state will see cost savings.   That said, some members of the health care system and the pharmaceutical industry say that policies such as upper payment limits could weaken access to life-saving drugs. Others say that the board has not engaged enough viewpoints from the health care industry. https://marylandmatters.org/2025/07/29/state-board-determines-two-type-2-diabetes-drugs-may-be-unaffordable/   XX One year after it was revealed that Chrissy Teigen and John Legend's son, Miles, was diagnosed with type 1 diabetes, Teigen is revealing how she's making her son feel more included. Teigen first opened up about her 7-year-old son's diagnosis after she and her two oldest kids, Miles and 9-year-old daughter Luna were at the 2024 summer Olympics cheering on Simone Biles. Teigen posted a photo of Miles and Luna holding up a sign. Also visible in the picture was the insulin pump on Miles' arm. Now, Teigen is sharing some insight into how she's making Miles more comfortable with having type 1 diabetes, including giving LeBron James' Barbie doll type 1 diabetes as well. In a video shared on Instagram, Teigen is seen taking the T1D Barbie, removing her insulin pump and gluing the pump onto LeBron James' Barbie. “Turning T1D Barbie into T1D Lebron James for my son,” Teigen captioned the video, revealing James is Miles' hero. 41 million followers https://www.yahoo.com/lifestyle/articles/chrissy-teigen-gives-lebron-james-154608782.html  

Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA. Marie returns to the program to unpack how AI and automation technologies are transforming drug safety workflows. Together with Emerj Editorial Director Matthew DeMello, she shares how IQVIA uses natural language processing (NLP) built on safety-specific training data to surface early signals from massive, multilingual datasets. She also explains why combining NLP with automation tools, such as RPA and OCR, leads to higher accuracy in adverse event detection, especially across social media and non-traditional data channels. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Michael Kleinrock, lead research director at IQVIA, joined Over the Counter to discuss the importance of his company's Understanding the Use of Medicines in the US 2025 report.

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody discovery with AI”.  In the first article, Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. In the second article, DDW Editor Reece Armstrong, speaks to Kashif Sadiq, Founder of DenovAI Biotech about the importance of computational methods in this field.

This episode focuses on how AI is transforming pharmacovigilance (PV) on a global scale, particularly focusing on the evolving role of local qualified persons for pharmacovigilance in the EU.This episode is presented in partnership with IQVIA.Host⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestAna Pedro Jesuíno, Global Head Local QPPV Network, IQVIADisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

人工模拟人体器官，这种科幻小说般的情节，正通过类器官技术变为现实。从疾病发现、药物研发到精准治疗……类器官和器官芯片技术正在重塑医学研究的格局和未来：它们不仅能够预测药物反应、优化肿瘤治疗方案，甚至有望改善器官移植的供体短缺问题。本期播客特别邀请到丹望医疗类器官药物平台负责人张龙博士，带领我们一起了解类器官技术，探索医学研究的体外宇宙。-嘉宾-张龙，丹望医疗，类器官药物平台负责人徐莹，IQVIA艾昆纬管理咨询部企业战略负责人莉莉安，《IQ老友说》主播-精华highlight-00:46 什么是类器官？01:31 目前的类器官技术只能模拟器官中很小的一个局部，但对疾病发现和药物研发都有重要价值06:41 类器官 vs. 传统的细胞系模型&小鼠模型，有哪些差异？07:07 从患者身上采样培养肿瘤类器官，就可以提前找到合适有效的药物组合10:29 费用&时间——为什么类器官受到投资者的青睐14:03 FDA 2025年4月新政：单克隆抗体药物研发中，将逐步取消动物实验15:13 一张“身份证”大小的器官芯片，可以模拟人体多个脏器之间的循环系统17:00 中国类器官的“未来已来”，政策对市场的刺激利好作用正逐渐显现19:32 目前类器官的技术壁垒有哪些？20:44 器官移植、人造肉、人造子宫…类器官或将如何改变我们的生活？23:43 类器官的未来，需要技术研发、商业化和监管法规的协同发展*本节目仅做信息交流之目的，嘉宾观点不代表任何公司立场- 制作团队 -沈旸、王心影、束菲滢- IQ老友说 -这是一档IQVIA艾昆纬的谈话类播客节目，聚焦医疗行业，网罗多元视角，激发观点碰撞，探寻新鲜洞见，让我们一起在轻松话聊的氛围中，老友说医疗，有趣又有料！- 关于IQVIA -IQVIA艾昆纬（纽交所代码：IQV）是全球领先的专注生命科学领域的高级分析、技术解决方案和临床研究服务供应商。IQVIA利用深入分析、前沿技术、大数据资源和广泛领域的专业知识，智能连接医疗生态的各个环节。IQVIA Connected Intelligence快速敏锐地为客户提供强大的数据洞察，帮助客户加速创新医疗的临床开发和商业化进程，以更好的医疗成果惠及患者。IQVIA拥有约88,000名员工，足迹遍布100多个国家/地区。IQVIA帮助生物科技、医疗器械、制药公司、医学研究者、政府机关、支付方以及其他医疗利益相关方，获得对疾病、人类行为和科技进步更深入的理解，共同朝着治愈各类疾病的方向迈进。- 互动方式 -关注IQVIA艾昆纬微信公众号，获取更多独家洞察！- 本节目由IQVIA出品，JustPod制作发行 -

Welcome to “Debunking Value, Access & Pricing Myths”—a podcast series from IQVIA's Value and Payer Evidence team where we separate fact from fiction on some of the most persistent misconceptions in the world of healthcare pricing and access.In this debut episode, your host Rebecca Coady, Principal at IQVIA, is joined by her colleague and EU HTA expert, Sian Tanner. Together, they take on a myth that's loomed large in the industry for decades: “A centralized EU HTA will never happen.”Sian, who leads IQVIA's EU HTA Solutions offering, unpacks what the reality of EU HTA implementation means for pharmaceutical teams across Europe. From challenges and timelines to strategic priorities and long-term implications for market access, they cover what you need to know—and what your team should be doing now to prepare.

Today we're talking to Hitesh Seth, Chief Architect for Financial Services & Insurance at Salesforce, and what struck me most is how he radiates genuine enthusiasm for what he does. After 25+ years in tech, he has so much fire and passion - and in this conversation, he shares how he keeps it going.Hitesh's story offers a completely different way to think about career growth and finding work that energizes rather than depletes you.You'll hear about:The mindset shift that changed everything: How he discovered that teaching others was actually the most selfish thing he could do Why he never feels bored at work: His approach to creating excitement and challenge within any roleThe power of following your curiosity: How staying genuinely interested in learning has been his career compassHow to know when it's time to move on: His rule about leaving when you want to accelerate your learning in new areasWhy passion beats planning: How his most meaningful career moves came from following what energized him, not following a prescribed pathThe "bug" you need to cultivate: That relentless drive to solve problems that keeps you up at night (in the best way)Building expertise while staying fresh: How to become deeply skilled without getting stuck in one narrow areaThe thread that weaves throughout this conversationHitesh's infectious passion for learning and problem-solving. You'll hear someone who has figured out how to stay genuinely excited about work by constantly growing, teaching others, and focusing on solving real problems that matter.About HiteshHitesh Seth is Chief Architect for Financial Services & Insurance at Salesforce, where he works with key customers globally on Data & AI/GenAI solutions. Hitesh also works closely with Salesforce Ventures teams for investing, acquisition and integration of startups/Fintechs. His career spans leadership roles at JPMorgan Chase, American Express, and IQVIA.He graduated from IIT Kanpur, is a patent holder, published author, and passionate mentor. From his early days discovering a computer in a small shop in India to leading cutting-edge technology architecture today, Hitesh exemplifies how curiosity and passion can lead to a fulfilling and thriving career.What this means for youIf you're feeling stuck, Hitesh's story shows that it's possible to build a career where you wake up excited about the challenges ahead. The key isn't finding the perfect job - it's cultivating the right mindset about learning, growth, and contribution.What resonated most with you from this conversation?Did his perspective on teaching as learning spark something for you? What resonated most with you? I'd love to hear - DM me on IG www.instagram.com/careerintechnicolor If you enjoyed this conversation, I invite you to follow the podcast and share it with someone who might need to hear this perspective! This helps more people discover these stories.Xo, BaibaSupport the show

In this episode of Denatured, Archana Hegde from IQVIA discusses the practical challenges faced by pharmacovigilance (PV) professionals as they navigate the FDA's first draft guidance for AI in drug development, published in January 2025. Hegde explains that the vagueness of the current framework is like “a recipe with no pictures and mystery ingredients." During the discussion, she highlights areas of existing confusion.This episode is presented in partnership with IQVIA.Host⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestArchana Hegde, Senior Director, PV Systems & Innovations, IQVIADisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

As AI threats are becoming more sophisticated and privacy laws and AI regulations are rapidly evolving, the need for transparency and responsible practices has never been greater.  Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

This episode of the Astonishing Healthcare podcast features Michael Kleinrock, Director, Research Development at the IQVIA Institute for Human Data Science. We explore key highlights from their most recent annual report - Understanding the Use of Medicines in the U.S. 2025 - with an eye toward implications for plan sponsors and the health benefits market. What are the key drivers of higher drug spend beyond GLP-1s? At what cost do consumers abandon prescriptions at the counter? How is biosimilar adoption going, and what impact is it having on trend? We answer these questions and many more, including how the IRA could impact innovation, vaccination rates, and what was most surprising to Michael in the data: hint, it's how much prices really changed year-over-year! Additional Reference Materials (IQVIA Institute Reports & Publications)Assessing the Biosimilar Void in the U.S.Proliferation of Innovation Over TimeRelated ContentAH048 - High-Cost Orphan Drugs, Securing Claims Data, and More, with Dr. Eric BrickerAH055 - Pharmacy Benefits 101: Stop-Loss Insurance, with Mike Miele, FSA, MAAAReplay - Innovative partnerships for GLP-1 management, with Vida HealthHow to Manage Pharmacy Benefit Spend in a GLP-1 WorldFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

Whether it's building trust or ecosystems, the key to effective consumer engagement is being open. This point was driven home repeatedly during this podcast from on the ground at Cannes.Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register!    AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket!    Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeanne Taylor Hecht, Chief Executive Officer and Chairwoman at Lexitas. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering: How Jeanne's various roles have equipped her to become a more rounded CEO and board member. How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice. Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat. Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS? Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients.  Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler's Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University's master's in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university's Ross School of Business. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

This episode focuses on how IQVIA is innovating with agentic AI to drive efficiency and quality in clinical trials.  In this episode you will:   Discover how agentic AI can be leveraged to enhance efficiency and quality in clinical trials and help increase the chance of success. See how an agentic AI approach can optimize site selection, trial design, and other critical elements in clinical trials. Learn about using agentic AI to identify new indications and targets in early clinical development by analyzing data from multiple databases. Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA's Research and Development Solutions.

In a dynamic regulatory environment, IQVIA's Michelle Gyzen suggests that AI may be the best and only way to keep with changes that are happening daily–and sometimes hourly.In this discussion Lori and Michelle touch on the governance frameworks for cybersecurity, risk, and how AI transformation and integration is evolving to help regulatory professionals navigate the speed and complexity of global requirements.Host⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestMichelle Gyzen, Sr. Director, Strategic Regulatory Solutions; Head of Regulatory Services Innovation & Technology, IQVIA

This week, Nicolle and Taylor from Finch Marketing are joined by Jeff Ward, our trusted partner at IQVIA, to break down how we harness the power of IQVIA's data to create laser-focused campaigns that convert for our clients. We explore the strategies behind smart targeting—and why precision beats broad strokes in today's digital landscape. Whether you're a startup or seasoned business, you'll walk away with tools to dial in your message and build deeper connections with your target audience. Tune in and get data-savvy!

Lori Ellis, head of insights and Ian Fisher, head of development of analytics at IQVIA, discusses the critical importance of Target Product Profiles (TPPs) for life sciences companies, especially during uncertain times with funding challenges. Fisher emphasizes that TPPs serve as strategic guiding light which help companies articulate their development goals and demonstrate value to potential investors and partners.This episode is presented in partnership with IQVIA.Host⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestIan Fisher, Head of Development Analytics, IQVIA

While few doubt the opportunity represented by real-world evidence, some concerns remain about its validity compared to traditional forms of clinical evidence, particularly among regulators. To address these concerns, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, suggests that incorporating some elements of traditional trials, such as randomization, is a good way to persuade regulators that RWE can be used for consumer health innovation, for example in generating new claims or supporting Rx-to-OTC switch. Looking forward, Spitzer is excited about the ways in which digital health tools and artificial intelligence can be used to expand the scope of RWE as well as drive personalization for consumers. Timestamps: 3:00 - Addressing concerns about RWE's scientific rigour and validity 12:00 – Regulators' views of RWE, particularly for consumer health 16:00 – Use of RWE for Rx-to-OTC switch 22:00 – The future of RWE Guest Bio: Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Spitzer has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.

大众以为的临床试验：参与试验就是当"小白鼠"，分到对照组等于"陪跑"？真实的临床试验：从争分夺秒抢入组率，到精益求精的数据清理；从被QA检查支配的恐惧，到和AI抢饭碗的焦虑。在第21个“5·20国际临床试验日”，我们邀请到三位来自IQVIA的临研人，带您走进临床试验的“幕后”故事。从入行5年的“螺丝工”，到从业10年的“端水大师”，以及深耕20年、见证行业变迁的资深临研人，他们将从各自的视角出发，用亲身经历述说：临床试验不是冰冷的数据，而是由每张高铁票、每通深夜电话、每个电子签名共同编织的生命守护网。收听本期节目，一同探索全球领先的CRO企业的“通关秘籍”与时代洞察！- 嘉宾 -冯祎恺，IQVIA艾昆纬临床运营高级总监肖婷，IQVIA艾昆纬临床运营高级经理牛金成，IQVIA艾昆纬临床运营高级监查员莉莉安，《IQ老友说》主播- 精华highlight -02:42 To临研求职者：CRO有哪些岗位03:46 抢时间、争入组、保质量是CRA工作的三要素06:09 从“救火员”到“消防局局长”，解密CRA向PM晋升的进阶之路09:51 不同于项目制，FSP以“人”为单位提供服务10:52 入组难——临研人的“至暗时刻”11:34 受试者≠小白鼠13:21 临床试验成功的定义不止一种，严格把关是对患者权益的守护，也是一种成功14:53 数据清理阶段的高频出差，是精益求精的临研人留下的足迹17:16 PM是一个协调各方的人肉背锅侠，既要具备端水大师的能力，也要有“预言家”的素质18:31 为什么说QA是办公室的“鬼见愁”？20:20 E人比I人更适合做CRA吗？24:57 快速适应CRA工作的秘诀是“脸皮厚”27:05 过去20年，临研一线对于CRO流程体系健全化的实感29:18 AI能取代临研人吗？30:26 从手写病例报告传真到电子知情，信息技术实现了许多临研人曾经的“梦想”32:59 To初出茅庐的临研人，不要害怕“拧螺丝”*本节目仅做信息交流之目的，嘉宾观点不代表任何公司立场- 制作团队 -沈旸、王心影、束菲滢- IQ老友说 -这是一档IQVIA艾昆纬的谈话类播客节目，聚焦医疗行业，网罗多元视角，激发观点碰撞，探寻新鲜洞见，让我们一起在轻松话聊的氛围中，老友说医疗，有趣又有料！- 关于IQVIA -IQVIA艾昆纬（纽交所代码：IQV）是全球领先的专注生命科学领域的高级分析、技术解决方案和临床研究服务供应商。IQVIA利用深入分析、前沿技术、大数据资源和广泛领域的专业知识，智能连接医疗生态的各个环节。IQVIA Connected Intelligence快速敏锐地为客户提供强大的数据洞察，帮助客户加速创新医疗的临床开发和商业化进程，以更好的医疗成果惠及患者。IQVIA拥有约88,000名员工，足迹遍布100多个国家/地区。IQVIA帮助生物科技、医疗器械、制药公司、医学研究者、政府机关、支付方以及其他医疗利益相关方，获得对疾病、人类行为和科技进步更深入的理解，共同朝着治愈各类疾病的方向迈进。- 互动方式 -关注IQVIA艾昆纬微信公众号，获取更多独家洞察！- 本节目由IQVIA出品，JustPod制作发行 -

Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA, who joins us to explore the overlooked intersection of AI and safety workflows in life sciences. As the industry experiences an explosion in the volume and diversity of data—from social media and call centers to audio and video files—Marie outlines the mounting challenges for pharmacovigilance and the opportunities AI is unlocking for healthcare and life sciences leaders. Marie discusses how advancements in voice-to-text transcription and automation are helping safety teams manage massive datasets, pinpoint potential risks, and reallocate human resources toward high-value activities like signaling and benefit-risk management. She also shares insights into where human expertise remains essential, particularly in interpreting complex clinical contexts that AI alone cannot fully capture. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

The potential for real world evidence (RWE) is huge, according to enthusiasts, but to the uninitiated it can seem like a complicated and forbidding subject. In this Over the Counter double episode, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, makes understanding real world evidence easy. We start with the basics, with what it is and what companies need to know about it, and what the key difference is with randomised control trials. Many companies are already using real world evidence, Volker notes, and he extracts some key lessons for companies interested in trying it out based on his extensive experience working with industry on such projects. Timestamps 2:00 – Introductions 4:00 – What is real world evidence? 5:00 – Can RWE and clinical trials complement each other? 10:00 – Why RWE is particularly attractive today 14:00 – Don't reinvent the wheel 18:00 – Why is this important for consumer health companies? 25:00 – Why RWE is often a good value option, especially for SMEs 33:00 – Applications of RWE in consumer health Guest Bio Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Volker has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.

Le vice-président américain JD Vance achève une visite en Inde où il y a rencontré le Premier ministre Narendra Modi, pendant laquelle les deux ont négocié au sujet des mesures tarifaires envisagées par Donald Trump. À l'ordre du jour notamment, les médicaments, car l'Inde est un géant de l'industrie pharmaceutique. C'est un euphémisme d'affirmer que les États-Unis sont extrêmement dépendants des médicaments produits en Inde : près d'un générique sur deux consommés y est fabriqué. On parle ici de traitements contre l'hypertension, les troubles de la santé mentale ou encore le diabète. Car il faut le rappeler, si l'Inde est le premier fournisseur de médicaments au monde, c'est aussi le premier fournisseur des États-Unis. L'an passé, ce sont près de 13 milliards de dollars de médicaments indiens qui ont été exportés sur le sol américain.Pourtant, avant la pause de Donald Trump et donc les négociations en cours, l'Inde était visée par les droits de douane américains, puisqu'il était question d'une surtaxe de 26%. Cela veut donc dire que tout produit fabriqué en Inde arrivant aux États-Unis pourrait être taxé à cette hauteur, y compris donc les médicaments.À lire aussiEn visite en Inde, J.D. Vance affiche son optimisme commercial et sa proximité idéologique avec Narendra ModiÉconomiquement avantageux, sanitairement dangereux Mais il ne s'agit pas de marchandises lambda : il est question de santé publique. La conséquence de l'application des mesures tarifaires de Donald Trump, c'est évidemment un risque sur la santé des Américains en raison d'une hausse des prix.Car les coûts de production en Inde sont trois à quatre fois moins élevés qu'aux États-Unis. Cela permet à Washington d'économiser des milliards de dollars en frais de santé. Rien qu'en 2022, d'après le cabinet de conseil IQVIA, les économies réalisées grâce aux génériques indiens se sont élevées à 219 milliards de dollars.Un pas vers Donald TrumpSi l'objectif de Donald Trump, c'est de relocaliser la production aux États-Unis, cela ne se fait pas du jour au lendemain. Les Américains ne disposent pas forcément des principes actifs sur leur sol pour fabriquer les médicaments en tant que tels. D'autant que leur deuxième fournisseur, c'est la Chine, pays le plus touché par les mesures du président américain. Devant telle situation, plusieurs géants européens présents en Inde notamment ont annoncé des investissements massifs aux États-Unis, avec l'ambition d'anticiper les hausses des prix. Le laboratoire Roche prévoit 50 milliards de dollars pour renforcer ses capacités de production et de diagnostic sur le sol américain. Novartis de son côté parle de 23 milliards sur cinq ans. Donc pour le moment, si on ne s'en tient qu'aux annonces, le président américain obtient des résultats. Mais pour toutes les raisons que l'on vient de détailler, Washington et New Delhi n'ont pas d'autres choix que de discuter. Le bras de fer est diplomatique, mais aussi économique. On a pu le voir ces dernières heures avec la visite de JD Vance à New Delhi. Sauf que la particularité, c'est qu'à court terme, pour les Américains, il est impossible de remplacer l'approvisionnement indien. Ces produits sont vitaux, car l'Inde est un véritable pilier de la santé aux États-Unis. C'est en fait l'un des meilleurs exemples de produit à demande inélastique, à savoir des produits dont on ne peut pas se passer. La question maintenant, c'est jusqu'à quel prix ! À lire aussiComment l'Union européenne compte éviter les pénuries de médicaments?  

This podcast features malaria experts Caroline Boulton (Global Program Head, Malaria, at Novartis); Sherwin Charles (CEO, Goodbye Malaria); and Carlos Chaccour (Researcher and Visiting Scholar, Navarra Institute for International Development). The conversation delves into the current malaria response, examining shifts in international funding, R&D innovations, drug resistance challenges, emerging prevention tools, and the impact of climate change.The podcast is hosted by IQVIA's Daniel Mora-Brito, Engagement Manager, Global Health, EMEA Thought Leadership.

In this episode, IQVIA MedTech experts Michelle Edwards and Michaela Miller discuss key trends shaping the MedTech industry in 2025. The conversation covers advancements in 3D printing, real-world evidence (RWE), and clinical AI, among others. Read Ten MedTech Trends to Watch in 2025 to learn more. https://www.iqvia.com/locations/united-states/library/insight-brief/ten-medtech-trends-to-watch-in-2025Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Michelle Edwards, Practice Lead, U.S. MedTech Real World and Clinical Solutions, IQVIA

This podcast episode features a discussion between Jeff Pilch from IQVIA and Sanjay Mistry from Molnlycke. Together, they explore the journey of how their companies collaborated to solve a significant business problem related to customer master data management (MDM). Sanjay explains the challenges Molnlycke faced in defining and managing customer data across different units, which hindered their ability to perform basic analytics and customer segmentation. Jeff and Sanjay then discussed the solutions proposed by IQVIA, emphasizing a practical, incremental approach to implementing MDM and data governance, which helped Molnlycke achieve better data management and business efficiency.Featured Speakers:Jeff Pilch - MDM Practice Lead, IQVIA Sanjay Mistry - Director Data Operations, Commercial Excellence at Molnlycke

On International HPV Awareness Day, Dr. Nicola Paul hosts Dr. Tando Gaqana, a passionate HPV vaccine advocate, and Daniel Mora-Brito, IQVIA's thought leader in global health, to discuss the impact of Human Papillomavirus (HPV) in South Africa, highlighting the importance of vaccination and regular screening to prevent HPV-related conditions in Africa.

James Hatfield is the Chief Revenue Officer at Liveswitch and with extensive leadership experience in companies like IQVIA and Sageworks. Liveswitch uses instant video to drive less, give more estimates, assess issues remotely, pre-qualify leads better, and document your work. With a simple click and no apps, LiveSwitch Contact is the fastest and easiest way to connect with customers and team members to make more money and save time. James co-founded a company that turned financial statements into plain language for small business owners, leading it to become an Inc. 500 company and eventually sold it to KKR. He emphasizes the importance of "grit" and resilience in business, especially in the face of rejection or adversity and advocates for collecting feedback and using it to improve your business, which he refers to as "delighting the customer." James recommends forming a personal board that includes people from different industries and backgrounds.   Website: LiveSwitch LinkedIn: James Hatfield   Check out our CEO Hack Buzz Newsletter–our premium newsletter with hacks and nuggets to level up your organization. Sign up HERE.  I AM CEO Handbook Volume 3 is HERE and it's FREE. Get your copy here: http://cbnation.co/iamceo3. Get the 100+ things that you can learn from 1600 business podcasts we recorded. Hear Gresh's story, learn the 16 business pillars from the podcast, find out about CBNation Architects and why you might be one and so much more. Did we mention it was FREE? Download it today!

This episode focuses on using AI for indication selection and prioritization to optimize the value of clinical development planning. In this episode you will:  Discover how AI can ensure faster, better clinical development and decision making to help get drugs to market faster. See how AI can be leveraged to prioritize hundreds of indications into high-potential opportunities rapidly. Learn about using AI to look at clinical trial data to help predict the future competitive intensity for an indication.  Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA's Research and Development Solutions.

Com o tempo seco, o nariz pode facilmente ficar ressecado e perder sua capacidade de filtrar as impurezas do ar. Por isso, fazer uma lavagem de alto volume no nariz diariamente com soro fisiológico pode ajudar em uma melhor respiração, e também diminuir aquela sensação de nariz entupido.Neste episódio, dr. Drauzio convida o médico otorrinolaringologista dr. Marcel Menon e a fisioterapeuta cardiorrespiratória Genai La Torre, para explicar como incorporar essa prática na rotina e a importância de manter a região sempre limpa.Conteúdo produzido em parceria com o Nasoar, a marca pioneira em lavagem nasal de alto volume no Brasil.¹Referência 1: IQVIA. PMB: Lançamento de MarcasVeja também: Como fazer lavagem nasal em crianças?

In this episode, Dr. Vishakha Sharma, Senior Principal Data Scientist at Roche Diagnostics shares her perspectives on the potential of GenAI to improve patient outcomes, enhance the efficiency of healthcare delivery, and reduce costs. She also addresses some of the key issues surrounding data interoperability and data integration when dealing with diverse data sources and unstructured data. The discussion brings attention to the need for guiding principles and highlights the ethical frameworks.Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Vishakha Sharma, Ph.D., Senior Principal Data Scientist, Roche Diagnostics

Georgie Kovacs is a seasoned professional with over two decades of healthcare expertise, having contributed to industry giants like Pfizer, Syneos Health, IQVIA, and Bristol-Myers Squibb. She launched Fempower Health in 2020, a pioneering platform that empowers women with evidence-based insights and support. Collaborating with top experts, Georgie is dedicated to redefining the narrative surrounding women's health, ensuring every woman has the knowledge and resources to thrive and make informed decisions about their health. In this episode, Georgie opens up about her personal and professional story, shaped by her roots as the daughter of Hungarian immigrants and the challenges of forging her path in the healthcare industry. Discover her unique approach to overcoming obstacles, her mental strength cultivated through long-distance running, and the lessons she's learned about breaking down big problems into manageable steps. Tune in for a conversation filled with vulnerability, grit, and actionable insights that will leave you inspired to tackle your own challenges head-on. Don't miss Georgie's powerful message about persistence, self-discovery, and creating a meaningful impact in the world. Website- https://www.fempower-health.com/ Social Media Links/Handles- https://www.instagram.com/fempowerhealth https://www.youtube.com/@fempowerhealth

Taking the first steps towards becoming a skills-based organisation is exciting—but what does it really take to get started? In this episode of the Digital HR Leaders Podcast, David Green sits down with Christophe Cabrera, Director and Head of IT Talent and Company Reputation at UCB, to share an honest look at the early days of their transformation. Unlike the polished success stories we often hear, this conversation is all about the reality of starting out: what works, what doesn't, and how to build momentum. Here's what you can expect: The biggest challenges in getting started, from outdated approaches to experimenting with AI How UCB used proof-of-concept to build confidence in AI-powered solutions Managing the complexities of a workforce spread across production, clinical and office roles Keeping their skills framework agile as new competencies emerge Defining what success looks like, with internal mobility and personalised learning leading the way This conversation, sponsored by TechWolf, is an honest and practical look at what it takes to get started with skills-based management. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Christophe Cabrera: LinkedIn MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

How can HR leaders design company cultures that are intentional, adaptive and aligned with business goals? To answer this question, in this episode of the Digital HR Leaders podcast, David Green sits down with Melissa Daimler, Chief Learning Officer at Udemy and author of ReCulturing: Design Your Company Culture to Connect with Strategy and Purpose for Lasting Success. With years of hands-on experience at Adobe, Twitter, WeWork, and now Udemy, Melissa brings a wealth of practical insights on how to build cultures that stand the test of change. Here's what you can expect from this conversation: How trends like skills-based strategies, AI and flexible working are reshaping workplace culture What a healthy culture really looks like—and how to build it intentionally How Udemy is aligning its culture with skills-focused goals and preparing for AI's growing impact Tips for staying clear and aligned as priorities shift rapidly Common missteps organisations make when trying to design culture—and how to avoid them This episode, sponsored by TechWolf, is packed with real-world advice and insights that HR and learning leaders can start applying right away. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Melissa Daimler: LinkedIn MyHRFuture Academy: MyHRFuture Insight222: Insight222 TechWolf: TechWolf Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company's platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez also discusses how this affects the potential of AI and ML. LINKS:    Bionavigen A-Alpha Bio Specifica 

What better way to learn about the makes or breaks of skills initiatives than from an organisation whose mission is to deliver reliable skills data across the workforce? Joined by Mikaël Wornoo, co-founder of TechWolf, host David Green explores how organisations can move beyond surface-level skills discussions to drive real business impact. Sharing lessons learned from working with global organisations, this episode covers: How organisations are innovatively applying skills data to solve business challenges Contrasts between US and European approaches to skills that could shape your global workforce strategy The hidden challenges that derail skills projects and what companies often miss when trying to “get started” The roles required to build a truly effective skills team Why AI isn't just the future of skills intelligence but the catalyst for shifting how organisations define and measure talent This episode, sponsored by TechWolf, isn't about skills for the sake of skills—it's about reframing workforce intelligence as a strategic lever for measurable business outcomes. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: TechWolf: TechWolf MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

On this episode host Fred Goldstein invites Elizabeth Powers, Vice President and General Manager, Regulatory Science and Study Innovation at IQVIA, to discuss Real World Evidence. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering: How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview Being the 'less educated person in the office', and using that to drive the growth of the business Opting not to leave after the sale of the business, and becoming the CEO Being the star player within a PE portfolio, leading to a quick exit to IQVIA Life lessons on having your cake...and eating it! Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality. Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world's leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In a world where artificial intelligence and workplace technologies are revolutionising how we work, the stakes have never been higher. How can organisations harness these powerful tools while ensuring fairness, ethics and compliance in a rapidly changing landscape? In this episode of the Digital HR Leaders podcast, host David Green sits down with Keith Sonderling, former Commissioner of the United States Equal Employment Opportunity Commission (EEOC), to tackle these critical questions. With a front-row seat to the challenges and opportunities at the intersection of AI and employment law, together, David and Keith explore: The promises of AI in HR—and the hidden risks leaders need to watch for How the global regulatory landscape is shaping the use of AI in the workplace Who's accountable when AI gets it wrong—and how liability is determined What HR tech vendors and HR leaders must do now to stay ahead of evolving regulations Real-world advice for embracing innovation without compromising on ethics or compliance Whether you're an HR leader navigating the rise of AI, a tech innovator shaping the future of work, or someone passionate about building a fairer workplace, this episode, sponsored by TechWolf is a must-listen. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Keith Sonderling: Keith Sonderling TechWolf: TechWolf MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

What can we learn from an organisation that has been a skills-based pioneer for over 30 years? At EPAM Systems, building a future-ready, skills-based workforce has been a foundational strategy, positioning the company as one of the most mature examples in the field. In this episode of the Digital HR Leaders podcast, host David Green is joined by Sandra Loughlin, Chief Learning Scientist at EPAM Systems, to discuss the lessons EPAM has learned over its decades-long journey and how organisations can apply these insights to their own skills transformations. Together, they dive into: The structure and strategy behind EPAM's skills-based evolution, shaped by 30 years of experience in skills management Common myths around skills-based organisations The importance of defining the work itself before pinpointing necessary skills Practical guidance on selecting the right technology to support skills-based practices Approaches to validating skills data, moving beyond self or manager assessments to more reliable data sources Insights on tailoring a skills strategy to different industries and functions, and determining when high-quality skills data is a must This episode, sponsored by TechWolf, is essential for HR leaders seeking to drive business impact through robust skills data and build a truly future-ready workforce. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Sandra Loughlin: Sandra Loughlin TechWolf: TechWolf MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

Join Rina Alexin as she hosts Aruna Adhikari, Head of Product Clinical Technologies at IQVIA, for a deep dive into the lessons and philosophies that shaped Aruna's successful career in product management. In this episode, Aruna shares insights from over two decades of experience, including her journey from electrical engineering to becoming a celebrated product leader in life sciences, recently named one of the “100 Most Inspiring People” by Pharma Voice. Discover Aruna's approach to leading with empathy, embracing humility, building cross-functional trust, and fostering a tenacious drive for innovation. Whether you're an emerging product manager or a seasoned executive, Aruna's story and wisdom offer valuable guidance on achieving meaningful, impactful product leadership.

In this episode you will: Discover how AI can predict the success of clinical trials in terms of efficacy, regulatory approval, operational feasibility, reimbursement attainment and product uptake. Learn why AI can give us deeper insights by analyzing unstructured data for better-informed clinical development decisions. See how an agentic AI approach can speed up what would take months and weeks manually, to days and hours, while looking at even more information for the analysis.   Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA's Research and Development Solutions

As barreiras burocráticas estão entre os fatores que impedem que inovações na área da saúde no Brasil cheguem aos pacientes. O estudo Fifarma W.A.I.T. (Waiting to Access Innovative Therapies) Indicator para a América Latina, conduzido pela IQVIA e pela Federação Latino-Americana da Indústria Farmacêutica (Fifarma) aponta que, entre 2014 e 2023, das 365 moléculas aprovadas pela FDA ou pela EMA – agências reguladoras de saúde nos Estados Unidos e na União Europeia, respectivamente –, apenas 222 receberam aprovação em pelo menos um país da América Latina. No Brasil, a situação é ainda mais preocupante: 23% dos medicamentos em cinco áreas terapêuticas cruciais estão disponíveis apenas no setor privado. Para Renato Porto, presidente executivo da Interfarma, “o principal obstáculo do Brasil encontra-se, justamente, na fase de incorporação, que de fato define quais medicamentos vão estar à disposição da população”. Ouça o bate-papo entre o presidente-executivo Renato Porto e a jornalista Bárbara Guerra, produzido pelo Estadão Blue Studio, com o patrocínio da Interfarma.See omnystudio.com/listener for privacy information.

In this episode of the Astonishing Healthcare podcast, Joe Murad, CEO of Vida Health, joins host Justin Venneri and Capital Rx Chief Clinical Officer Sara Izadi, PharmD, in the studio for a discussion about glucagon-like peptide-1 (of GLP-1) medications and how partnering to manage cardiometabolic health can help plan sponsors control costs and keep their populations healthy. Joe and Sara review the latest data, including the rising prevalence of obesity and diabetes, GLP-1 discontinuation rates, the robust GLP-1 pipeline, and they highlight the innovative partnership between Capital Rx and Vida. Together, they explore the importance of appropriate patient management, education, and support, nuances of GLP-1 prescribing like dose titration, the role of digital health technology in achieving effective healthcare outcomes and coordinating care with other providers, and what to watch for in 2025.Related ContentHow to Manage Pharmacy Benefit Spend in a GLP-1 WorldAH021 - Managing Pharmacy Costs in a GLP-1 World, with Bridget MulvennaGLP-1s are No Laughing MatterSourcesHow many adults with private health insurance could use GLP-1 drugs (KFF; 9/5)GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes (JAMA; 5/24)Poll: 1 in 8 Adults Say They've Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease (KFF; 5/10)The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028 (IQVIA; 5/7)For more information about Capital Rx and this episode, please visit Capital Rx Insights.

Tune in to the latest episode of the IQVIA SFE Insights Podcast as Lakshdeep Singh, Senior Principal at IQVIA, and Goksu Dogan, Senior Principal in the Artificial Intelligence and Machine Learning Solutions team, explore the role of predictive analytics and real-time triggers in optimizing HCP engagement and improving patient outcomes. Discover how AI/ML-powered solutions are revolutionizing the pharmaceutical industry and providing actionable insights that drive better business results. Don't miss this insightful discussion!

Dr. Lillian Siu and Dr. Melvin Chua discuss the new technologies and novel therapeutics that were featured at the 2024 ASCO Breakthrough meeting. TRANSCRIPT Dr. Lillian Siu: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Lillian Siu, a medical oncologist and director of the Phase 1 Trials Program at the Princess Margaret Cancer Center in Toronto, Canada, and a professor of medicine at the University of Toronto. On today's episode, we'll be discussing key takeaways from the 2024 ASCO Breakthrough meeting in Yokohama, Japan. Joining me for this discussion is Dr. Melvin Chua, who served as the chair of Breakthrough's Program Committee. Dr. Chua is the head of the Department for Head, Neck and Thoracic Cancers in the Division of Radiation Oncology at the National Cancer Center in Singapore. Our full disclosures are available in the transcript of this episode. Dr. Chua, it's great to be speaking with you today and congratulations on a very successful Breakthrough meeting. Dr. Melvin Chua: Thanks Dr. Siu. It was really inspiring to come together again to showcase the innovative work of world-renowned experts, clinicians, researchers, med-tech pioneers, and drug developers from around the globe. Our theme this year was inclusivity and thus it was important to bring people together again in the Asia Pacific region and to foster international collaborations that are so important in advancing cancer care. This year, we invited 65 international faculty, of which 55% were from Asia. Also, importantly, we achieved approximately a 50-50 split for male to female representation. These are remarkable statistics for the meeting, and we really hope to retain this for future Breakthrough [meetings]. Dr. Lillian Siu: The meeting featured renowned keynote speakers who shared great insights on new technologies and therapies that are shaping the future of drug development and care delivery. Let's first talk about artificial intelligence and the keynote address by Dr. Andrew Trister. He gave a very interesting talk titled, “Plaiting the Golden Braid: How Artificial Intelligence Informs the Learning Health System.” What are the key messages from his talk? Dr. Melvin Chua: Couldn't agree with you more, Dr. Siu. Dr. Trister is the chief medical and scientific officer of Verily, a precision health company. He previously worked in digital health and AI at The Bill and Melinda Gates Foundation, and worked at Apple where he led clinical research and machine learning with Apple partners. But perhaps it was really his background and training as a radiation oncologist that was most pertinent as he was able to weave both the components of new AI models and the applications and pitfalls in the clinic to the audience. Dr. Trister provided a very high-level view through the history of AI and showcased the progression of the different AI models and he basically explained between deep and shallow methods as well as deductive logic versus inductive probabilistic methods. He then provided several clinical examples where these models have shown their utility in the clinic, for example, pathology and so forth. At the same time, he illustrated several pitfalls with these models. So overall, I think Dr. Trister's talk was very well received by the audience with several key messages, including the importance of [using] high-quality data as the basis of a good AI model. AI was also addressed in an Education Session that looked at Artificial Intelligence in the Cancer Clinic. And we had a panel of experts that highlighted current progress and successes with AI in the clinic, advances with AI assisted pathology for clinical research and precision medicine, large language models (LLMs) for applications in the clinic, and how we could leverage AI in precision oncology. And from this session, I had several key takeaways. Dr. Alexander Pearson [of the University of Chicago] gave a very illustrative talk on how multimodal information across clinical omics, radiological information and multi omics could be used to improve diagnostic tasks and clinical prediction across different cancers. And Dr. Joe Yeong [of Singapore General Hospital] gave a very good talk on how AI can be applied in digital pathology to accelerate research in immunology and help in the development of immunotherapies. Dr. Danielle Bitterman [of Brigham and Women's Hospital] shared very good examples of how LLMs could be used in a clinic. And I think the example that really stood out for me was how LLMs could be deployed to create responses to patient queries. And of course, the big question in the room was: How could AI eventually encapsulate compassion in their response? I think this again showcased how LLMs could really help to accelerate our clinical work going forward. And ultimately circling back to data, Dr. Caroline Chung [of MD Anderson] gave a very poignant description on the importance of data quality and how poor-quality data could eventually lead to underperforming AI models. So all in all, I think this was a great session. And what do you think, Dr. Siu? Dr. Lillian Siu: Melvin, I totally agree with you. I like all your comments and I really enjoyed the keynote as well as the session on AI in the cancer clinic chaired by Dr. Pearson. I think all these sessions were really informative. Discussions on the latest AI and machine learning, algorithms and technologies on digital pathology, LLMs and big data, as you said, really enables the attendees, especially clinicians like me, to gain a deep understanding of how AI can be translated to practical applications. Dr. Melvin Chua: Great. So, Dr. Siu, let's talk about some of the novel therapeutics that were featured at the meeting. Again, this was an important session for Breakthrough, and it's always been there. So could you share some highlights from the sessions on novel drug development from your perspective? Dr. Lillian Siu: Yes, indeed. Drug development is such an exciting aspect of this meeting. On Day 3 of the meeting, we had a keynote by Dr. Shimon Sakaguchi of Osaka University, who discussed “Targeting Regulatory T cells (Tregs) in Cancer: The Science, Trials, and Future.” And he talked about T cells, especially Treg biology, the role of Tregs in immune regulation, new developments in Treg immuno-oncology drugs, and how we can actually target Tregs to treat early cancers, etc. This talk is particularly exciting because there are now anti CCR8 antibodies in the clinic that specifically target Tregs, and some early signals of anti-tumor activities are already being observed. Dr. Sakaguchi also emphasized the importance of combination sequence and timing of drugs for the successful use of cancer immunotherapeutic agents. I also want to emphasize the Education Session that followed, titled, “The Future of Immunotherapy, New Drugs and New Ideas.” In that particular session, we heard about engineering T-cell immunity to eradicate tumors. We heard about CAR T-cell therapy in GI cancers, novel immunotherapeutic combinations, and T-cell engagers, which are bispecifics in cancer. While success with some of these immunotherapeutic modalities, such as cell therapies and T-cell engagers have been largely seen in hematological malignancies, we are beginning to observe efficacy signals in solid tumors. For example, the CAR T targeting Claudin18.2 in gastrointestinal cancers and the recently approved FDA-approved DLL3/CD3 bispecific T-cell engager, tarlatamab, in small cell lung cancer are really exciting examples. We also heard from investigators who are exploring neoadjuvant therapies in the neoadjuvant therapy session, and the key takeaway from that session is that we have growing interest in using neoadjuvant therapy or perioperative therapy. In other words, neoadjuvant plus adjuvant therapy in different cancers. In the neoadjuvant session, there were updates provided by different experts on the roles of neoadjuvant therapy in melanoma, liver cancer, bladder cancer, and nasopharyngeal cancer. Increasingly, there is randomized trial evidence to support the use of neoadjuvant therapy or perioperative immunotherapy in several cancer types with survival-based endpoints. Very exciting indeed. Dr. Melvin Chua: Indeed, I couldn't agree with you more. I think one of the things that went into designing the case-based discussions this year was that we wanted to talk about cancers that were relevant to this part of the world and hence we again showcased lung cancers, gastric cancers and melanomas, and whereby we have again perspectives from an expert from the West coupled to an expert from the East, thereby showcasing the diversity of practice around the world. The other thing that we did this year was we decided to pair the case-based discussions with the keynotes and the Education Sessions as well. For example, on Day 3, we had Dr. Sakaguchi speak on Tregs, as you mentioned. And this was followed by an in-depth session on new immunotherapies, and then followed by a case-based discussion on different melanoma cases on the role of neoadjuvant immunotherapy in this disease, and the strikingly relevance of response to prognostication. This is an important trait that we're seeing now that seems to pan out across different cancers, where we find that neoadjuvant response to combination systemic therapies and/or radiotherapy is a strong prognosticator. Dr. Lillian Siu: So, Dr. Chua, we've discussed some breakthrough treatments and promising advances in cancer care, and we've touched upon some barriers to success in cancer treatment. I would like to ask you about the keynote address by Dr. Raffaella Casolino of the World Health Organization, who spoke passionately about efforts by the WHO and its partners to build equity in cancer care. Can you share some highlights with us? Dr. Melvin Chua: Absolutely, Dr. Siu. In spite of the tremendous advances we've seen in recent years in oncology, there are still major disparities in cancer care, such as cost and access, which affect patients worldwide. I think Dr. Casolino's talk was a very nice overview whereby she showed, first of all, the WHO's impact in terms of the WHO Cancer Resolution initiative that was implemented in 2017, where through this initiative, WHO has impacted 100 countries, invested $1 billion in funds, and that has led to millions of lives saved. But she then really drilled down to some of the key examples of the focus of the WHO in terms of equalizing care in cancer. I think one which struck me was the appreciation of the disparities in the clinical trials landscape. I think it is clear that there's still a huge barrier to clinical trials between the high- and middle-income countries and the low- and middle-income countries, and the majority of clinical trials these days are industry sponsored and we really need to look at leveling the playing field in this regard. Then she highlighted the WHO's work on trying to lower the barriers to precision oncology. And I think there are several issues in that sense, but I think what the WHO has really worked hard on is promoting education for genomic medicine, where they've done several reviews with experts around the world to educate the field across the world on how we interpret and apply genomics in the clinic. So all in all, it was very interesting to hear Dr. Casolino's insights from a policy perspective, and again, this emphasizes that there's so much work to be done at the end of the day and the dialogue needs to continue. We also heard about policy, academic and industry perspectives in the context of clinical trials, and that led to a discussion on real-world evidence generation for regulatory approvals. It was very nice that we had a session on that at the end of Breakthrough 2024 (Real-World Evidence and Clinical Trials: Beyond the Ivory Tower). And in that session, we heard from Dr. Shaalan Beg [of the NIH], and Dr. Janet Dancey [of Queen's University] who represented views from academia and Dr. Hidetoshi Hayashi [of Kindai University Hospital] shared perspectives on decentralized trials. I'd like to encourage our listeners to watch these sessions if they were unable to attend. The content is very rich, and I'm sure they'll learn from it. Dr. Lillian Siu: Thank you so much, Dr. Chua. Is there anything else you would like to cover before we wrap up the podcast today? Dr. Melvin Chua: Thank you, Dr. Siu. The thing I really want to emphasize is, apart from all these Educational Sessions and having very eminent keynote speakers, one of the key points that we really want to bring out for Breakthrough is to showcase the high-quality research. This year we had 300 abstracts submitted and they were all high quality, cutting across trials, omics research, AI and technology, and eventually we selected 235 of them and we were able to showcase some of them across three oral sessions over three days. I think this is an important component of Breakthrough that we really wish to continue building upon where people are now excited to use this forum to present their work. Dr. Lillian Siu: Thank you so much, Dr. Chua. I really enjoyed our discussions today. I look forward to seeing how the Breakthrough meeting will continue to grow in future years. Dr. Melvin Chua: Thank you again, Dr. Siu. Thank you for all your leadership and efforts in making Breakthrough a successful meeting series the past few years. Dr. Lillian Siu: Thank you to our listeners for your time today. You'll find links to the session discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Lilian Siu  @lillian_siu  Dr. Melvin Chua  @DrMLChua    Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. Lillian Siu:  Leadership (Immediate family member): Treadwell Therapeutics  Stock and Other Ownership Interests (Immediate family member): Agios    Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen   Dr. Melvin Chua:  Leadership, Stock and Other Ownership Interests: Digital Life Line  Honoraria: Janssen Oncology, Varian  Consulting or Advisory Role: Janssen Oncology, Merck Sharp & Dohme, ImmunoSCAPE, Telix Pharmaceuticals, IQVIA, BeiGene  Speakers' Bureau: AstraZeneca, Bayer, Pfizer, Janssen   Research Funding: PVmed, Decipher Biosciences, EVYD Technology, MVision, BeiGene, EVYD Technology, MVision, BeiGene  Patents, Royalties, Other Intellectual Property: High Sensitivity Lateral Flow Immunoassay for Detection of Analyte in Samples (10202107837T), Singapore. (Danny Jian Hang Tng, Chua Lee Kiang Melvin, Zhang Yong, Jenny Low, Ooi Eng Eong, Soo Khee Chee)    

Discomfort Power.Drayton Virkler, President and Chief Commercial Officer at Fortrea, shares his guiding mantra that's led to ground breaking initiatives and results in his 23 years in the life sciences industry from the US to Singapore. This leadership philosophy pushes boundaries and drives innovation and excellence.Just wait until you hear the stories for how he's applied it...... from his work at top firms like Fortrea, IQVIA, and Certara, where's redefined success by challenging norms and embracing the power of discomfort.Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. They have 19,000 people working in more than 90 countries and are scaled to deliver focused and agile solutions to customers globally.LinkedIn Profile https://www.linkedin.com/in/draytonvirklerCompany Link: https://www.fortrea.com/What You'll Discover in this EpisodeWhy His Mantra is “Get Comfortable Being Uncomfortable”.The Worst Leadership Advice He's Heard.The Important Lesson He Learned Working in the Family Business.The One Trait He'd Like to Instill in Every Employee..Why Experiences are “Tools” in Your Career “Toolbox”.A Twist in His Career That Accelerated His Growth-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

Today's guests are Tom Hayes and Gareth Dabbs, Senior Director of Product Strategy & Commercialization and Global Technology Product Strategy Lead at IQVIA, respectively. In today's episode, they come to share two use cases helping to drive quality patient experiences between healthcare and insurance workflows. The first focuses on optimizing omnichannel marketing for compliance. The second use case centers on building trust and value in caretaker support systems through personalized insights. If you've enjoyed or benefited from some of the insights in this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

We're still processing the Super Bowl, but in the meantime, we wanted to share an awesome conversation from Radio Row last week in Las Vegas. Ashley had the chance to sit down with her longtime friend Christina Mack for a conversation that touched on everything from the health benefits of team sports to letting go of “mom guilt” to the power of female friendships. Christina is the Chief Science Officer at global healthcare company IQVIA, and a lead sports science researcher for the NFL and NBA, or as Ashley often explains it, “she has a badass job.” A highly respected voice in the professional sports industry, she frequently presents to owners on injuries, concussions, and the safety of the game. She's also an advocate for women in STEM, a mom of three awesome kids, and a superlative scavenger-hunt-maker. This may be one of our shorter episodes, but it's chock full of incredible insights about being a parent, a professional, and a friend.Thanks as always for listening, please subscribe wherever you get your podcasts! And a reminder you can watch this episode on our YouTube channel.Questions, comments or feedback? Email: ashley@yourmom.co.See you next week!

Ralph welcomes Professor John Kindt to discuss his recent article in the Capitol Hill Citizen, "Time to Criminalize Internet Gambling." Then, our resident international law expert Bruce Fein takes us to the International Court of Justice and explains the lawsuit that South Africa has filed against Israel, which alleges genocide. Finally, Ralph has some choice words about Boeing's latest disaster. John Kindt is Professor Emeritus of Business Administration at the University of Illinois Gies College of Business, where his teaching focuses on—among other topics—the socio-economics of gambling and legal policies. Mr. Kindt has frequently testified as an expert witness before state legislative and congressional committees.Illinois was one of the first states to get the so-called riverboat casinos. And of course, this was just deployed to bring casinos everywhere to Illinois and to other states. They promise what we call “the E's” — they'll help education, they'll help the environment, they'll help the elderly, they'll help employment. None of that is accurate. They just throw nickels and dimes at this.John KindtI feel very comfortable naming names of these companies. If you just talk about “Big Gambling”, you're nowhere near specific accountability. When you talk about specific names of companies, the next step is the names of the CEOs, the names of the Directors of Marketing and Advertising. You find out whether there are any whistleblowers.Ralph NaderBruce Fein is a Constitutional scholar and an expert on international law.  Mr. Fein was Associate Deputy Attorney General under Ronald Reagan and he is the author of Constitutional Peril: The Life and Death Struggle for Our Constitution and Democracy, and American Empire: Before the Fall.To my mind, this perhaps is the strongest case in the history of the Genocide Convention…Literally hundreds of officials from the highest levels of the Netanyahu administration have openly stated, “We are going to lay a siege. No water, no food, no medicine, no shelter, no hospitals.” You can't survive under those conditions… And they've also stated clearly that in their view, Palestinians are animals and will be treated accordingly. Many statements saying, “They need to be driven out of Gaza. They don't deserve to be there.” These are the most flagrant, direct confessions of a genocidal intent that's imaginable.Bruce FeinThe FAA has inspection offices up in Seattle and they go to the Boeing factories all the time, but they've been rather lax over the years— to put it mildly. They have delegated regulatory authority to Boeing to regulate itself, and then they do the paperwork at the FAA… There's going to be more and more disclosures, and it will come right back to the lack of regulatory enforcement and prosecution of the culpable executives who have turned a once-proud engineering aerospace company into a speculative tool to increase the stock price on Wall Street.Ralph NaderIn Case You Haven't Heard with Francesco DeSantisNews 1/10/241. In response to Israel's campaign of destruction in Gaza, South Africa has filed a lawsuit at the International Court of Justice alleging that Israel's actions “‘are genocidal in character because they are intended to bring about the destruction of a substantial part' of the Palestinians in Gaza,” per PBS News Hour. Israel – which PBS acknowledges “has a history of ignoring international tribunals,” – intends to send a legal team to the Hague to fight this case.2. South Africa is joined in this case by a number of states, including the Organization of Islamic Countries, the Plurinational state of Bolivia, Jordan, Turkey, and Malaysia, according to Al Jazeera. Some high-profile individuals have also signed on, most notably Israeli Leftist MK Ofer Cassif, who said “My constitutional duty is to Israeli society and all its residents, not to a government whose members and its coalition are calling for ethnic cleansing and even actual genocide.” Common Dreams reports that in retaliation, Right-wing Israeli MKs are seeking to expel Cassif from the Knesset.3. Speaking to Democracy Now!, Professor Francis Boyle – the only lawyer to have ever successfully won a Genocide Convention case at the ICJ – said “I believe South Africa will win an order against Israel to cease and desist from committing all acts of genocide against the Palestinians.” He added that Israel has historically heeded orders from the U.S. to cease attacks on Palestine, meaning “We here in the United States of America have the power to stop this.”4. Leaking anonymously to the Guardian, extremism experts at the Anti-Defamation League are expressing outrage at the organization's attempts to draw “false equivalences,” between anti-Semitism and Left-wing anti-Zionism, emphasizing that such equivocation undermines their mission to stop anti-Semitic hate. One ADL employee went so far as to say “The ADL has a pro-Israel bias and an agenda to suppress pro-Palestinian activism.” Since October 7th, the ADL has “been working with law enforcement to crack down on college campus activism … [developing] a legal strategy to go after branches of Students for Justice in Palestine… [and describing] grassroots calls for protests of Israel's military campaign as ‘pro-Hamas activism'.”5. A stunning report in the Intercept reveals that “Whether reporting from the Middle East, the United States, or anywhere else across the globe, every CNN journalist covering Israel and Palestine must submit their work for review by the news organization's bureau in Jerusalem prior to publication.” While CNN corporate claims this does not significantly impact their coverage of Israel and Palestine issues, a CNN staffer, speaking anonymously for fear of reprisal, disputes this claim – saying “Every single Israel-Palestine-related line for reporting must seek approval from the [Jerusalem] bureau — or, when the bureau is not staffed, from a select few handpicked by the bureau and senior management.” As Jim Naureckas of FAIR puts it, “When you have a protocol that routes all stories through one checkpoint, you're interested in control, and the question is who is controlling the story?”6. President Biden is facing a campaign staff revolt related to his policy on Gaza, POLITICO reports. In a letter, 17 current Biden campaign staffers wrote “As your staff, we believe it is both a moral and electoral imperative for you to publicly call for a cessation of violence…Complicity in the death of over 20,000 Palestinians, 8,200 of whom are children, simply cannot be justified.” Beyond the clear moral imperative of this plea, the staffers emphasize that this is a form of “tough love,” intended to help Biden avert electoral catastrophe come November, already ominously portended by “volunteers quit[ting] in droves,” over Gaza.7. Over 130 constituents of Representative Elise Stefanik, along with groups representing District members and concerned citizens, sent a letter to the Congresswoman this week decrying her conduct in the recent hearings that led to the ouster of the presidents of Harvard and the University of Pennsylvania. The letter excoriated Rep. Stefanik for charging the university presidents with anti-Semitism while herself full-throatedly endorsing the ongoing genocide in Gaza, ending with the clear demand “Resign and let us be done with you!”8. The Federal Trade Commission has won a temporary block of IQVIA's Acquisition of Propel Media, according to a statement released by the Commission. The FTC sought to block this merger because “the proposed acquisition would give IQVIA a market-leading position in programmatic advertising targeted to doctors and other health care professionals.” Senator Elizabeth Warren congratulated the FTC on social media, writing “This court win is the [FTC's] fourth merger victory in the health care industry in less than a month. [Lina Khan] continues to fight for more competition and against bad deals that would raise health care prices for consumers.”9. You may have heard about the recent Boeing 737 MAX 9 crisis, in which a violent explosive decompression event resulted in a door plug blowing out of the plane while in midair. Amid the flurry of information coming out about this story, it is worth highlighting the response by the Association of Flight Attendants, headed by labor icon Sara Nelson: “Our union supports the FAA's quick and decisive action to ground certain 737 MAX 9[s] that do not meet the inspection cycles specified in the Emergency Airworthiness Directive. This is a critical move to ensure the safety of all crew and passengers, as well as confidence in aviation safety. Lives must come first always. Last night's incident could have been worse, but Flight Attendants and Pilots of Alaska 1282 ensured all passengers and crew arrived safely back on the ground. We commend the entire crew. We are closely monitoring and working with our airlines - Alaska and United - the FAA, and DOT to ensure that aircraft are not returned to service until they are deemed safe for all. AFA is also participating in the NTSB investigation and we support that process for full safety findings and actions. Flight Attendants are aviation's first responders. We are trained for emergencies, and we work every flight for aviation safety first and foremost. We fly only when it's safe.”10. Finally, taking notice of the recent, groundbreaking Senate hearing on Corporate Crime, the Washington Post devoted an entire column to the issue. Focusing on the costs of corporate crime, the paper notes “The size and scope of corporate crime are massive, with an annual price tag exceeding $300 billion, according to FBI data…street crime…by comparison, is a meager $16 billion.” Furthermore, the Post repeated Senator Durbin's lamentation that the Department of Justice lacks resources “to battle deep-pocketed corporations,” sending a message that “if you've got enough money, you can game the system and walk away with…billions when it's…over.” In his closing remarks, Durbin wondered aloud, “What does it say about the system of justice in America…if the big guys are exempt and the little guys go to jail…?”This has been Francesco DeSantis, with In Case You Haven't Heard. Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

In this episode right leaning comedian Nick Di Paolo talks about Battered border patrol, Bad signs and more! Support our sponsor, Nugenix! Support the podcast & get a free bottle of Nugenix Total T when you text 231-231 & use the keyword NICK. Texting enrolls you into recurring automated text messages. Consent not required to purchase. Message and data rates may apply. #1 Doctor recommended brand by primary care physicians based on an independent survey conducted by IQVIA, 2022. Like what you hear?  Get TWICE as much "Nick Di Paolo Show", full episodes of Steven Crowder's “Louder with Crowder” show and more on Mug Club! Sign up today to get all their content at https://Nickdip.com and use the promo code NICKDIP to get your first month FREE! For Tour Dates, Merch, stand-up clips and more visit https://nickdip.com